Notably, Ian R Hardy and colleagues have proposed the use of monoclonal antibodies targeting CD79B as a means to collectively suppress B cells and prevent autoimmunity, with the added benefit of facilitating rapid immune recovery, unlike other approaches that induce B cell death (43). This evidence concerns the gene CD79B and Autoimmunity.